Molina Andrea, Veramendi Jon, Hervás-Stubbs Sandra
Instituto de Agrobiotecnología, Universidad Pública de Navarra-CSIC, Campus Arrosadía, 31006 Pamplona, Spain.
Virology. 2005 Nov 25;342(2):266-75. doi: 10.1016/j.virol.2005.08.009. Epub 2005 Sep 2.
The 2L21 epitope of the VP2 protein from the canine parvovirus (CPV), fused to the cholera toxin B subunit (CTB-2L21), was expressed in transgenic tobacco chloroplasts. Mice and rabbits that received protein-enriched leaf extracts by parenteral route produced high titers of anti-2L21 antibodies able to recognize the VP2 protein. Rabbit sera were able to neutralize CPV in an in vitro infection assay with an efficacy similar to the anti-2L21 neutralizing monoclonal antibody 3C9. Anti-2L21 IgG and seric IgA antibodies were elicited when mice were gavaged with a suspension of pulverized tissues from CTB-2L21 transformed plants. Combined immunization (a single parenteral injection followed by oral boosters) shows that oral boosters help to maintain the anti-2L21 IgG response induced after a single injection, whereas parenteral administration of the antigen primes the subsequent oral boosters by promoting the induction of anti-2L21 seric IgA antibodies. Despite the induced humoral response, antibodies elicited by oral delivery did not show neutralizing capacity in the in vitro assay. The high yield of the fusion protein permits the preparation of a high number of vaccine doses from a single plant and makes feasible the oral vaccination using a small amount of crude plant material. However, a big effort has still to be done to enhance the protective efficacy of subunit vaccines by the oral route.
犬细小病毒(CPV)VP2蛋白的2L21表位与霍乱毒素B亚基(CTB - 2L21)融合,在转基因烟草叶绿体中表达。通过非肠道途径接受富含蛋白质的叶提取物的小鼠和兔子产生了高滴度的能够识别VP2蛋白的抗2L21抗体。在体外感染试验中,兔血清能够中和CPV,其效力与抗2L21中和单克隆抗体3C9相似。用来自CTB - 2L21转化植物的粉碎组织悬液灌胃小鼠时,可诱导产生抗2L21 IgG和血清IgA抗体。联合免疫(单次非肠道注射后口服加强剂)表明,口服加强剂有助于维持单次注射后诱导的抗2L21 IgG反应,而非肠道给予抗原通过促进抗2L21血清IgA抗体的诱导来启动随后的口服加强剂。尽管诱导了体液反应,但口服递送诱导的抗体在体外试验中未显示中和能力。融合蛋白的高产量使得从单一植物制备大量疫苗剂量成为可能,并使得使用少量粗制植物材料进行口服疫苗接种成为可行。然而,要通过口服途径提高亚单位疫苗的保护效力仍需付出巨大努力。